首页> 外文期刊>Hormone research in p?diatrics >Bone Mineral Density Corrected for Size in Childhood Leukaemia Survivors Treated with Haematopoietic Stem Cell Transplantation and Total Body Irradiation
【24h】

Bone Mineral Density Corrected for Size in Childhood Leukaemia Survivors Treated with Haematopoietic Stem Cell Transplantation and Total Body Irradiation

机译:骨矿物质密度校正儿童白血病幸存者大小,用血液生物干细胞移植治疗及全身照射

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Childhood leukaemia survivors treated with haematopoietic stem cell transplantation and total body irradiation (HSCT-TBI) have multiple risk factors for reduced bone mineral density (BMD) and growth failure; hence, BMD assessment must take body size into consideration. This study aimed to evaluate size-corrected BMD in leukaemia survivors treated with and without HSCT-TBI. Methods: Childhood leukaemia survivors treated with HSCT-TBI (n = 35), aged 17.3 (10.5-20.9) years, were compared with those treated with chemotherapy only, (n = 16) aged 18.5 (16.1-20.9) years, and population references. Outcome measures included anthropometric measurements and BMD by dualenergy X-ray absorptiometry. BMD was corrected for size as bone mineral apparent density (BMAD). Statistical analysis was performed by 1- and 2-sample t tests as well as regression analysis (5% significance). Results: HSCT-TBI survivors were lighter and shorter with reduced spinal heights compared with chemotherapy-only subjects and population references. Compared with population references, HSCT-TBI survivors showed lower BMD standard deviation scores (SDS) (p = 0.008), but no difference in BMAD-SDS, and chemotherapy-only survivors showed no differences in neither BMD-SDS nor BMAD-SDS. All HSCT-TBI participants with BMD-SDS -2 had BMAD-SDS -2. BMAD-SDS was negatively associated with age (r = -0.38, p = 0.029) in HSCT-TBI survivors. Conclusions: Size-corrected BMD are normal in HSCTTBI survivors in young adulthood, but may reduce overtime. BMD measurements should be corrected for size in these patients to be clinically meaningful. (C) 2018 S. Karger AG, Basel.
机译:背景:儿童白血病患者用血吞咽细胞移植治疗和总体辐射(HSCT-TBI)对骨密度(BMD)和生长失效有多种危险因素;因此,BMD评估必须考虑到身体规模。本研究旨在评估用HSCT-TBI治疗的白血病幸存者中矫正矫正BMD。方法:使用HSCT-TBI(n = 35)治疗的儿童白血病幸存者,17.3岁(10.5-20.9)岁,仅与含化疗处理的人(n = 16),年龄18.5(16.1-20.9)岁及人口参考。结果测量包括Dualenergy X射线吸收测量的人体测量测量和BMD。 BMD被校正为骨矿物表观密度(BMAD)。通过1-和2样品T测试和回归分析(5%意义)进行统计分析。结果:与唯一只有疗程和人口引用相比,HSCT-TBI幸存者较轻,脊柱高度降低,脊柱高度降低。与人口引用相比,HSCT-TBI幸存者显示出低于BMD标准偏差分数(SDS)(P = 0.008),但BMAD-SDS没有差异,并且在BMD-SDS NOR BMAD-SDS中没有差异。具有BMD-SDS的所有HSCT-TBI参与者具有BMAD-SDS& -2。 BMAD-SDS在HSCT-TBI幸存者中与年龄(R = -0.38,p = 0.029)负相关。结论:尺寸矫正BMD在年轻成年期的HSCTTBI幸存者中是正常的,但可能会减少加班。应校正BMD测量,以便在这些患者中校正临床有意义。 (c)2018年S. Karger AG,巴塞尔。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号